Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T. Yokoe T, et al. Among authors: maeda t. Breast Cancer. 2021 May;28(3):581-591. doi: 10.1007/s12282-020-01192-y. Epub 2021 Jan 2. Breast Cancer. 2021. PMID: 33389616 Free PMC article.
Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
Ozaki Y, Aoyama Y, Masuda J, Inagaki L, Kawai S, Shibayama T, Maeda T, Kurata M, Yoshida K, Saeki S, Hosonaga M, Fukada I, Hara F, Kobayashi T, Kobayashi K, Miyake S, Takano T, Ueno T, Ohno S. Ozaki Y, et al. Among authors: maeda t. BMC Cancer. 2022 Jan 4;22(1):36. doi: 10.1186/s12885-021-09128-1. BMC Cancer. 2022. PMID: 34983437 Free PMC article.
Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer.
Inoue Y, Fujishima M, Ono M, Masuda J, Ozaki Y, Maeda T, Uehiro N, Takahashi Y, Kobayashi T, Sakai T, Osako T, Ueno T, Ohno S. Inoue Y, et al. Among authors: maeda t. Breast Cancer Res Treat. 2022 Nov;196(2):341-348. doi: 10.1007/s10549-022-06726-w. Epub 2022 Sep 24. Breast Cancer Res Treat. 2022. PMID: 36153381 Free PMC article. Review.
Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.
Hosonaga M, Habano E, Arakawa H, Kaneko K, Nakajima T, Hayashi N, Fukada I, Nakamura A, Haruyama Y, Maeda T, Inari H, Kobayashi T, Nakashima E, Ueno T, Takano T, Takahashi S, Ohno S, Ueki A. Hosonaga M, et al. Among authors: maeda t. Breast Cancer. 2024 Sep;31(5):988-996. doi: 10.1007/s12282-024-01612-3. Epub 2024 Jul 17. Breast Cancer. 2024. PMID: 39017822 Free PMC article.
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study.
Aoyama Y, Ozaki Y, Kizawa R, Masuda J, Kawai S, Kurata M, Maeda T, Yoshida K, Yamashita N, Nishimura M, Hosonaga M, Fukada I, Hara F, Kobayashi T, Takano T, Ueno T. Aoyama Y, et al. Among authors: maeda t. Breast Cancer. 2024 Dec 7. doi: 10.1007/s12282-024-01657-4. Online ahead of print. Breast Cancer. 2024. PMID: 39644440
5,620 results